Venlafaxine XR in the treatment of anxiety

Objective: To present the results of numerous studies that assessed the eff icacy, safety and tolerability of venlafaxine extended release (XR) in trea ting anxiety disorders, particularly generalized anxiety disorder (GAD). Method: Efficacy was assessed with the Hamilton Rating Scale for Anxiety, C linical Global Impressions scale, Hospital Anxiety and Depression scale and other instruments. Standard safety and tolerability assessments were used. Results: In four placebo-controlled trials, venlafaxine XR was effective an d well tolerated in patients with GAD. Several additional smaller studies f ound venlafaxine XR effective in treating anxiety associated with social ph obia, obsessive-compulsive disorder and panic disorder. Conclusion: Venlafaxine XR has both short- and long-term efficacy and toler ability in treating symptoms of long-term anxiety and comorbid anxiety and depression, and in achieving remission in GAD patients. These characteristi cs, combined with early onset of anxiolytic action and dose-response effect , make it a logical choice for treating anxiety occurring alone or comorbid ly with depression.